Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.

摘要: PURPOSE: Capromab pendetide (ProstaScint) is an indium In 111 ((111)In)-labeled monoclonal antibody to prostate-specific membrane antigen (PSMA) used image prostate cancer. The appropriate techniques for obtaining images with this modality and the clinical indications study are in process of being optimized. MATERIALS AND METHODS: From 1994 2000, 631 imaging studies (111)In capromab were performed. accuracy utility primary staging patients disease at high risk metastasis recurrent or residual after therapy evaluated. RESULTS: high-risk evaluated lymph node metastases prior pelvic dissection, was found have a positive predictive value (PPV) 62%, negative (NPV) 72%, sensitivity specificity 72%. prostatic fossa recurrence using needle biopsy as gold standard, PPV 50%, NPV 70%, 49%, 71%. CONCLUSIONS: better than those computed tomography magnetic resonance detection soft-tissue nodal from has been demonstrated metastasis. Patients also may benefit selection salvage therapy. Innovative methods use radiation treatment planning under development.